1400682-90-7

Upstream product

• 1310349-96-2 (R)-2-methyl-propane-2-sulfinic acid [(R)-1-(5-bromo-2-fluoro-phenyl)-2,2-difluoro-3-hydroxy-1-methyl-propyl]-amide 
• 590-17-0 cyanomethyl bromide 
• 198477-89-3 1-(5-bromo-2-fluorophenyl)ethan-1-one 
• 1310349-83-7 (R)-3-(5-bromo-2-fluoro-phenyl)-2,2-difluoro-3-((R)-2-methyl-propane-2-sulfinylamino)-butyric acid ethyl ester 

Downstream Products

• 1346145-77-4 (R)-2-(3-amino-3-(5-bromo-2-fluorophenyl)-2,2-difluorobutoxy)acetonitrile 
• 1346145-84-3 (R)-5-(5-bromo-2-fluorophenyl)-6,6-difluoro-5-methyl-2,5,6,7-tetrahydro-1,4-oxazepin-3-amine 
• 1346145-86-5 (R)-N-(bis(4-methoxyphenyl)(phenyl)methyl)-5-(5-bromo-2-fluorophenyl)-6,6-difluoro-5-methyl-2,5,6,7-tetrahydro-1,4-oxazepin-3-amine 

Relevant academic research and scientific papers

1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention relates to 1,4 Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention relates to 1,4-Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pres

1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention relates to 1,4-Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pres

2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS

This invention relates to compounds of the formula (I), wherein A, B and R1 to R7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as 5 medicam